- Pfizer's (NYSE:PFE) group president of its Innovative Health Division Albert Bourla says a strengthening U.S. dollar will make international sales a tougher slog for U.S. companies who have a significant international presence (all medical large caps). Pfizer, for example, generates about half its sales outside of the U.S.
- Since the election of Donald Trump, the greenback peaked on January 3, rising over 6% against rival currencies on expectations that his policies will boost growth. It has fallen a bit since then, down over 3%, on Mr. Trump's comments that the dollar is "too strong" for U.S. firms to compete with their Chinese rivals.
- Source: Financial Times